Does Mtori Base Immunosuppression Offer Survival Advantage After Liver Transplantation for Hepatocellular Carcinoma? Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Hepatol Forum

Publisher Kare Publishing

Specialty Gastroenterology

Date 2023 May 30

PMID 37250931

Authors

Ali ALoun

Ez El Din Abu-Zeid

Ibrahim Umar Garzali

Affiliations

Soon will be listed here.

Abstract

Recurrence is still a problem after liver transplant for hepatocellular carcinoma (HCC). We performed an updated systematic review and meta-analysis of randomized controlled trials comparing tumor recurrence of mammalian target of rapamycin inhibitors (mTORi) versus Calcineurin inhibitor-based immunosuppression after liver transplantation for HCC. A systematic search was conducted in the following databases: MEDLINE, EMBASE, and Cochrane Central Register of Control Trials databases. The Medical Subject Headings used in the search included: "sirolimus," "everolimus," "mTORi," "HCC," "mTORi," "hepatic transplantation" "randomized controlled trials," and "liver transplantation (LT)". Seven randomized controlled trials were included for meta-analysis. There were a total of 1,365 patients, with 712 of these patients receiving calcineurin inhibitors (CNIs) while 653 had received mTORi. Our meta-analysis revealed that patients that received mTORi-based immunosuppression had superior recurrence-free survival (RFS) at 1 year and 3 years with a hazard ratio of 2.02 and 1.36, respectively. Meta-analysis also showed that within the first 3 years after LT for HCC, patients receiving CNIs-based immunosuppression have a higher recurrence than those receiving mTORi-based immunosuppression. Our meta-analysis revealed that recipients of mTORi-based immunosuppression had a superior OS at 1 year and 3 years. mTORi-based immunosuppression is associated with decreased early recurrence and improved RFS and overall survival.

Citing Articles

Renal metastasis of hepatocellular carcinoma after living donor liver transplantation.

Nakamura Y, Kamei J, Tanaka R, Yasunaga Y, Akamatsu N, Taguchi S IJU Case Rep. 2025; 8(2):133-137.

PMID: 40034914 PMC: 11872214. DOI: 10.1002/iju5.12826.

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.

De Simone P, Precisi A, Lai Q, Ducci J, Campani D, Marchetti P Cancers (Basel). 2024; 16(7).

PMID: 38610921 PMC: 11010831. DOI: 10.3390/cancers16071243.

mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.

Zhang L, Liu P, Zhuang L, Ling S, Zhan Q, Zhou W Mol Biomed. 2024; 5(1):9.

PMID: 38461206 PMC: 10924815. DOI: 10.1186/s43556-024-00170-6.

2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations.

Kumar A, Acharya S, Singh S, Duseja A, Madan K, Shukla A J Clin Exp Hepatol. 2023; 14(1):101269.

PMID: 38107186 PMC: 10724697. DOI: 10.1016/j.jceh.2023.08.005.

References

Schnitzbauer A, Filmann N, Adam R, Bachellier P, Bechstein W, Becker T . mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Ann Surg. 2020; 272(5):855-862. DOI: 10.1097/SLA.0000000000004280. View

De Simone P, Nevens F, De Carlis L, Metselaar H, Beckebaum S, Saliba F . Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012; 12(11):3008-20. PMC: 3533764. DOI: 10.1111/j.1600-6143.2012.04212.x. View

Wang P, Xu Y, Sun Y, Cheng J, Zhou K, Wu S . Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int. 2020; 41(3):562-573. DOI: 10.1111/liv.14734. View

Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C . Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013; 19(7):675-89. DOI: 10.1002/lt.23658. View

Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A . Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010; 10(10):2252-62. DOI: 10.1111/j.1600-6143.2010.03128.x. View

Choi H . Current status and outcome of liver transplantation in South Korea. Clin Mol Hepatol. 2021; 28(1):117-119. PMC: 8755474. DOI: 10.3350/cmh.2021.0381. View

El-Domiaty N, Saliba F, Vibert E, Karam V, Sobesky R, Ibrahim W . Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome. Transplantation. 2020; 105(8):1778-1790. DOI: 10.1097/TP.0000000000003434. View

Basu A, Banerjee P, Contreras A, Flynn E, Pal S . Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One. 2011; 6(8):e23919. PMC: 3160347. DOI: 10.1371/journal.pone.0023919. View

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

10.

Schnitzbauer A, Schlitt H, Geissler E . Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Transplantation. 2011; 91(11):1173-6. DOI: 10.1097/TP.0b013e318215e72b. View

11.

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

12.

Filgueira N . Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J Hepatol. 2019; 11(3):261-272. PMC: 6447422. DOI: 10.4254/wjh.v11.i3.261. View

13.

Serrano M, Sabroso S, Esteban L, Berenguer M, Fondevila C, Lorente S . Mortality and Causes of Death After Liver Transplantation: Analysis of Sex Differences in a Large Nationwide Cohort. Transpl Int. 2022; 35:10263. PMC: 9124758. DOI: 10.3389/ti.2022.10263. View

14.

Wang Z, Luo L, Cheng Y, He G, Peng B, Gao Y . Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood. J Gastrointest Surg. 2017; 22(4):633-639. PMC: 5869875. DOI: 10.1007/s11605-017-3619-3. View

15.

Lerut J, Iesari S, Foguenne M, Lai Q . Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?. Transl Gastroenterol Hepatol. 2017; 2:80. PMC: 5676205. DOI: 10.21037/tgh.2017.09.06. View

16.

Geissler E, Schnitzbauer A, Zulke C, Lamby P, Proneth A, Duvoux C . Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation. 2015; 100(1):116-25. PMC: 4683033. DOI: 10.1097/TP.0000000000000965. View

17.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

18.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Lee K, Kim S, Yoon K, Lee J, Cho J, Hong S . Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial. J Clin Med. 2020; 9(10). PMC: 7600292. DOI: 10.3390/jcm9103264. View